Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of shareholding changes and does not contain financial performance data.
Material Changes
The filing reports increases in the notional interests of specific PDMRs in GSK Ordinary Shares. These changes resulted from the re-investment of dividends paid on shares held in the GlaxoSmithKline Deferred Investment Award Programme. The transactions occurred at a price of 1,412.75 pence per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director share transactions.
Important Facts for Investors
- Transaction Type: Increases in notional share interests via dividend re-investment.
- Share Price: 1,412.75 pence per Ordinary Share.
- Involved Parties: Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Notification Date: GSK was advised of these changes on January 12, 2015.
- Signatory: Victoria Whyte, Company Secretary.